WO1997030972A1 - Process for the preparation of ng-monomethyl-l-arginine hydrochloride - Google Patents
Process for the preparation of ng-monomethyl-l-arginine hydrochloride Download PDFInfo
- Publication number
- WO1997030972A1 WO1997030972A1 PCT/EP1997/000760 EP9700760W WO9730972A1 WO 1997030972 A1 WO1997030972 A1 WO 1997030972A1 EP 9700760 W EP9700760 W EP 9700760W WO 9730972 A1 WO9730972 A1 WO 9730972A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydrochloride
- monomethyl
- formula
- compound
- arginine hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C277/00—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C277/08—Preparation of guanidine or its derivatives, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups of substituted guanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
Definitions
- the present invention relates to a process for the preparation of N G - monomethyl-L-arginine hydrochloride (L-NMMA hydrochloride).
- the present invention provides a process for the preparation of N G - monomethyl-L-arginine hydrochloride comprising:
- L-ornithine or an acid addition salt thereof preferably a hydrochloride salt thereof, wherein L is a leaving group; with L-ornithine or an acid addition salt thereof, preferably a hydrochloride salt thereof, in a suitable polar solvent, for example, water, optionally in the presence of a base followed by:
- L is a leaving group as would be understood by a person skilled in the art. Most suitably, L is the group:
- R 1 , R 2 , and R 3 are independently selected from hydrogen, halo, C ⁇ alkyl, C ⁇ alkoxy, and aryl, including fused aryl (ie where either R 1 and R 2 or R 2 and R 3 together with the carbon atoms to which they are attached form an aryl group fused to the pyrazole).
- L may also be C ⁇ alkoxy or C ⁇ cycloalkoxy. In the most preferred aspect of the invention, L is unsubstituted pyrazole.
- aryl means a 5 to 10 membered mono- or bi- cyclic aromatic system optionally including 1 to 3 heteroatoms selected from nitrogen, sulphur, and oxygen wherein the aromatic system is optionally substituted by 1 to 5 groups selected from halo, C ⁇ alkyl, and C ⁇ alkoxy. Suitable examples of such aryl substituents include phenyl and naphthyl.
- the term "halo" means fluoro, chloro, bromo or iodo.
- the base used in step (i) may be any inorganic or organic base which liberates the free form of the compound of formula (I) and/or of L-omithine and which, in the presence of hydrochloric acid, forms a by-product which is soluble in the solvent mixture produced in step (iii) of the reaction.
- the most preferred base is lithium hydroxide.
- alkyl or aromatic amines such as imidazole may also be suitable.
- the present invention provides a process for the preparation of N G -monomethyl-L-arginine hydrochloride comprising:
- Step (iv) isolation of N G -monomethyl-L-arginine hydrochloride may proceed at high pH, such as pH 9 to 12; however it is preferable to maintain a pH in the range 10 to 11, for example between 10 and 10.5 by addition of acid, for example concentrated hydrochloric acid.
- the reaction is suitably carried out at a non-extreme temperature, such as 0 ⁇ C to 70°C, for example 0°C to 50°C, most preferably 10 to 30°C, most conveniently at ambient temperature.
- step (ii) the hydrochloric acid is preferably added to give a pH of around 4.5 such that the mono-hydrochtoride salt is obtained in optimal yield.
- step (iii) the purpose of the alcoholic solvent is to act as a solvent for the by ⁇ products of the reaction and as a non-solvent for the product N G -monomethyl-L- arginine hydrochloride. Therefore, the invention includes within its scope, any variation of step (iii), for example, substitution of the alcoholic solvent which fulfils this purpose.
- step (iv) the product L-NMMA hydrochloride may be isolated directly from the reaction mixture by crystallisation, for example by adding seed crystals of L- NMMA hydrochloride and stirring the reaction mixture at a non-extreme temperature, such as -5°C to 30°C most conveniently at ambient temperature.
- the resultant product may optionally be further purified, for example by recrystallisation from a suitable solvent or mixture of solvents.
- the present invention provides the novel intermediates of formula (I), such as pyrazole carboxamidine and salts thereof, in particular pyrazole carboxamidine hydrochloride.
- the intermediates of formula (I) are commercially avavilable or may be prepared from commercially available starting materials by standard methods of chemistry, for example, by reaction of the appropriate pyrazole with methyl cyanamide.
- Cyanogen bromide (21.2g) was dissolved in tetrahydrofuran (THF) (150ml) with sodium carbonate (42.4g) present. The whole was stirred and cooled to between -10 to 20°C and over this range of temperature, methylamine (2M solution in THF, 100ml) was added over 10 minutes. The stirred reaction mixture was then left to react for 2 hours at -15 to 20°C, then allowed to warm to 10°C before filtering off the solid sodium salts to give a clear solution of methylcyanamide in THF.
- THF tetrahydrofuran
- reaction mixture was then allowed to cool with stirring and a few crystals of presolidified product added. A cake of product resulted, this was broken up and stirred to give an off white solid/liquid mixture. To this was added diethyl ether (50ml) with stirring, then the whole was filtered to give an off white waxy solid. The solid was dried in vacuo at 50°C to give 22.6g of a cream solid product, mp 153-154°C. NMR analysis showed it to contain ca 5% pyrazole.
- 1H-Pyrazole-1-N-methylcarboxamidine hydrochloride (12.85g), prepared as described in part (b), and L-ornithine hydrochloride (8.43g) were mixed in water, pH 2 to 3.
- Lithium hydroxide monohydrate (5.45g) was added to give a pH of 10.1.
- the pH was brought down and maintained between 10 and 10.5 with concentrated hydrochloric acid. After 3-4 days stirring at room temperature between this pH range no ornithine was detected by t.l.c. silica (0.88NH 3 /MeOH 15:35).
- reaction mixture was brought to pH 4.5 with concentrated hydrochloric acid (-5ml), then ethanol (200ml) added. A few seed crystals of N G -monomethyl-L- arginine hydrochloride were added and the whole stirred at room temperature for 3 days giving a white crystalline precipitate. This was filtered off to give 6g of the title product, mp 219-221°C with gas evolution.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a process for the preparation of NG-monomethyl-L-arginine hydrochloride comprising reaction of a compound of formula (I) or an acid addition salt thereof, wherein L is a leaving group; with L-ornithine or an acid addition salt thereof.
Description
PROCESS FOR THE PREPARATION OF Nc-MONOMETHYL-L-ARGININE HYDROCHLORIDE
The present invention relates to a process for the preparation of NG- monomethyl-L-arginine hydrochloride (L-NMMA hydrochloride).
A process for preparing NG-monomethyl-L-arginine and related compounds has been described in WO94/26701. On a large scale, this process suffers from the drawback that L-NMMA has to be isolated by column chromatography.
Preparation of L-NMMA hydrochloride is also described in WO94/02453. The methods described in this publication would, however, be unsuitable for a commercial process.
An improved synthesis of NG-allyl-(L)-arginine is described by Benatowicz et al in Synthetic Communications, 22 (5), 657-661 (1993). This process used fiavianic acid and ion exchange chromatography to isolate the product.
We have now discovered a new process for the preparation of L-NMMA hydrochloride where the product can be isolated directly from the reaction mixture without the need for chromatography. The new process also results in higher yields and an improved impurity profile of the product.
Accordingly, the present invention provides a process for the preparation of NG- monomethyl-L-arginine hydrochloride comprising:
(i) reaction of a compound of formula (I)
or an acid addition salt thereof, preferably a hydrochloride salt thereof, wherein L is a leaving group;
with L-ornithine or an acid addition salt thereof, preferably a hydrochloride salt thereof, in a suitable polar solvent, for example, water, optionally in the presence of a base followed by:
(ii) acidification to pH 4 to 5 with hydrochloric acid; then
(iii) addition of an alcoholic solvent, such as ethanol or industrial methylated spirit; then
(iv) isolation of NG-monomethyl-L-arginine hydrochloride.
In the compound of formula (I), L is a leaving group as would be understood by a person skilled in the art. Most suitably, L is the group:
wherein R1, R2, and R3 are independently selected from hydrogen, halo, C^alkyl, C^alkoxy, and aryl, including fused aryl (ie where either R1 and R2 or R2 and R3 together with the carbon atoms to which they are attached form an aryl group fused to the pyrazole). However, L may also be C^alkoxy or C^cycloalkoxy. In the most preferred aspect of the invention, L is unsubstituted pyrazole.
In the definition of L the term "aryl" means a 5 to 10 membered mono- or bi- cyclic aromatic system optionally including 1 to 3 heteroatoms selected from nitrogen, sulphur, and oxygen wherein the aromatic system is optionally substituted by 1 to 5 groups selected from halo, C^alkyl, and C^alkoxy. Suitable examples of such aryl substituents include phenyl and naphthyl.
In the definition of L, the term "halo" means fluoro, chloro, bromo or iodo.
The base used in step (i) may be any inorganic or organic base which liberates the free form of the compound of formula (I) and/or of L-omithine and which, in the presence of hydrochloric acid, forms a by-product which is soluble in the solvent mixture produced in step (iii) of the reaction. For economy and convenience, the most preferred base is lithium hydroxide. However, alkyl or aromatic amines such as imidazole may also be suitable. As would be understood by the skilled person, where the free forms of both the compound of formula (I) and of the L-ornithine are used, it may be possible to effect the reaction without adding a further base, otherwise the base is required.
According to a preferred aspect, the present invention provides a process for the preparation of NG-monomethyl-L-arginine hydrochloride comprising:
(i) reaction of pyrazole carboxamidine hydrochloride,
N
CHJNH NH
.HCl
with L-ornithine hydrochloride,
in a suitable polar solvent, for example, water, in the presence of lithium hydroxide followed by:
(ii) acidification to pH 4 to 5 with hydrochloric acid; then
(iii) addition of an alcoholic solvent, such as ethanol or industrial methylated spirit; then
(iv) isolation of NG-monomethyl-L-arginine hydrochloride.
During Step (i), the reaction may proceed at high pH, such as pH 9 to 12; however it is preferable to maintain a pH in the range 10 to 11, for example between 10 and 10.5 by addition of acid, for example concentrated hydrochloric acid. The reaction is suitably carried out at a non-extreme temperature, such as 0βC to 70°C, for example 0°C to 50°C, most preferably 10 to 30°C, most conveniently at ambient temperature.
During step (ii), the hydrochloric acid is preferably added to give a pH of around 4.5 such that the mono-hydrochtoride salt is obtained in optimal yield.
In step (iii), the purpose of the alcoholic solvent is to act as a solvent for the by¬ products of the reaction and as a non-solvent for the product NG-monomethyl-L- arginine hydrochloride. Therefore, the invention includes within its scope, any variation of step (iii), for example, substitution of the alcoholic solvent which fulfils this purpose.
In step (iv) the product L-NMMA hydrochloride may be isolated directly from the reaction mixture by crystallisation, for example by adding seed crystals of L- NMMA hydrochloride and stirring the reaction mixture at a non-extreme temperature, such as -5°C to 30°C most conveniently at ambient temperature. The resultant product may optionally be further purified, for example by recrystallisation from a suitable solvent or mixture of solvents.
As would be clear to a person skilled in the art, the compound of formula (I) used in the process of present invention may be replaced by methylcyanamide and this variation forms a further embodiment of the present invention.
In a further embodiment, the present invention provides the novel intermediates of formula (I), such as pyrazole carboxamidine and salts thereof, in particular pyrazole carboxamidine hydrochloride. The intermediates of formula (I) are commercially avavilable or may be prepared from commercially available starting materials by standard methods of chemistry, for example, by reaction of the appropriate pyrazole with methyl cyanamide.
Synthetic Example
(a) Preparation of methylcyanamide
Cyanogen bromide (21.2g) was dissolved in tetrahydrofuran (THF) (150ml) with sodium carbonate (42.4g) present. The whole was stirred and cooled to between -10 to 20°C and over this range of temperature, methylamine (2M solution in THF, 100ml) was added over 10 minutes. The stirred reaction mixture was then left to react for 2 hours at -15 to 20°C, then allowed to warm to 10°C before filtering off the solid sodium salts to give a clear solution of methylcyanamide in THF.
(b) Preparation of 1 H-pyrazole-1-N-methylcarboxamidine hydrochloride
Pyrazole (13.62g) was added to methylcyanamide solution (250ml) prepared as described in part (a) and then a hydrogen chloride solution (4M in dioxane 53ml) added. Upon addition of the hydrogen chloride a faint white precipitate appeared momentarily then dissolved. No significant exotherm was noted. The whole was heated with stirring at reflux for 2 hours forming a yellow liquid layer.
The reaction mixture was then allowed to cool with stirring and a few crystals of presolidified product added. A cake of product resulted, this was broken up and stirred to give an off white solid/liquid mixture. To this was added diethyl ether (50ml) with stirring, then the whole was filtered to give an off white waxy solid. The solid was dried in vacuo at 50°C to give 22.6g of a cream solid product, mp 153-154°C. NMR analysis showed it to contain ca 5% pyrazole.
1H NMR (DMSO-d6), δppm : 3.55 (s, 3); 6.78 (s, 1); 8.09 (s, 1); 8.9 (s, 1).
(c) Preparation of NG--monomethvl-L-arαinine hydrochloride
1H-Pyrazole-1-N-methylcarboxamidine hydrochloride (12.85g), prepared as described in part (b), and L-ornithine hydrochloride (8.43g) were mixed in water, pH 2 to 3. Lithium hydroxide monohydrate (5.45g) was added to give a pH of 10.1. A cream suspension formed which changed to a yellow solution after 1 to
2 hours and a pH of ca 11. The pH was brought down and maintained between 10 and 10.5 with concentrated hydrochloric acid. After 3-4 days stirring at room temperature between this pH range no ornithine was detected by t.l.c. silica (0.88NH3/MeOH 15:35).
The reaction mixture was brought to pH 4.5 with concentrated hydrochloric acid (-5ml), then ethanol (200ml) added. A few seed crystals of NG-monomethyl-L- arginine hydrochloride were added and the whole stirred at room temperature for 3 days giving a white crystalline precipitate. This was filtered off to give 6g of the title product, mp 219-221°C with gas evolution.
1HNMR (D20), δ ppm : 1.6 (m, 2); 1.82 (q, 2); 2.74 (s, 3); 3.15 (t, 2); 3.7 (t, 1).
Claims
C AIMS
A process for the preparation of NG-monomethyl-L-arginine hydrochloride comprising:
(i) reaction of a compound of formula (I):
or an acid addition salt thereof, wherein L is a leaving group;
with L-ornithine or an acid addition salt thereof, in a suitable polar solvent, optionally in the presence of a base followed by:
(ii) acidification to pH 4 to 5 with hydrochloric acid; then
(iii) addition of an alcoholic solvent; then
(iv) isolation of NG-monomethyl-L-arginine hydrochloride.
2. A process according to claim 1 wherein the compound of formula (I) is
or an acid addition salt thereof, wherein R , R2, and R3 are independently selected from hydrogen, halo, C^alkyl, C^alkoxy, and aryl, including fused aryl.
A process accordingly to claim 1 or 2 wherein the compound of formula (I) is
or an acid addition salt thereof.
4. A process according to any of claims 1 to 3 wherein the compound of formula (I) is in the form of a hydrochloride salt and a base is used in step
(i).
5. A process according to any of claims 1 to 4 wherein the compound of formula (I) is reacted with L-ornithine hydrochloride and a base is used in step (i).
6. A process according to any of claims 1 to 5 wherein lithium hydroxide is used as a base in step (i).
7. A process for the preparation of NG-monomethyl-L-arginine hydrochloride comprising:
(i) reaction of pyrazole carboxamidine hydrochloride,
CH3NH NH
.HCl
with L-ornithine hydrochloride, 
in a suitable polar solvent, in the presence of lithium hydroxide followed by:
(ii) acidification to pH 4 to 5 with hydrochloric acid; then
(iii) addition of an alcoholic solvent; then
(iv) isolation of NG-monomethyl-L-arginine hydrochloride.
8. A process according to any of claims 1 to 7 whereing the resultant NG- monomethyl-L-arginine hydrochloride is further purified.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97903315A EP0882014A1 (en) | 1996-02-20 | 1997-02-18 | Process for the preparation of n?g -monomethyl-l-arginine hydrochloride |
| JP9529780A JP2000504738A (en) | 1996-02-20 | 1997-02-18 | Method for producing N-upper G-monomethyl-L-arginine hydrochloride |
| AU17916/97A AU1791697A (en) | 1996-02-20 | 1997-02-18 | Process for the preparation of ng-monomethyl-l-arginine hydrochloride |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9603522.5A GB9603522D0 (en) | 1996-02-20 | 1996-02-20 | Chemical process |
| GB9603522.5 | 1996-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1997030972A1 true WO1997030972A1 (en) | 1997-08-28 |
Family
ID=10789060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1997/000760 Ceased WO1997030972A1 (en) | 1996-02-20 | 1997-02-18 | Process for the preparation of ng-monomethyl-l-arginine hydrochloride |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0882014A1 (en) |
| JP (1) | JP2000504738A (en) |
| AR (1) | AR005903A1 (en) |
| AU (1) | AU1791697A (en) |
| CO (1) | CO4761060A1 (en) |
| GB (1) | GB9603522D0 (en) |
| ID (1) | ID15968A (en) |
| PE (1) | PE43198A1 (en) |
| TW (1) | TW370520B (en) |
| WO (1) | WO1997030972A1 (en) |
| ZA (1) | ZA971398B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1197486A1 (en) * | 2000-10-13 | 2002-04-17 | Degussa AG | Process for the preparation of 1H-pyrazole-1-carboxamidines |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994002453A1 (en) * | 1992-07-24 | 1994-02-03 | The Wellcome Foundation Limited | Ng-monomethyl-l-arginine hydrochloride derivatives and their use in the treatment of septic shock |
-
1996
- 1996-02-20 GB GBGB9603522.5A patent/GB9603522D0/en active Pending
-
1997
- 1997-02-14 TW TW086101688A patent/TW370520B/en active
- 1997-02-18 WO PCT/EP1997/000760 patent/WO1997030972A1/en not_active Ceased
- 1997-02-18 JP JP9529780A patent/JP2000504738A/en active Pending
- 1997-02-18 EP EP97903315A patent/EP0882014A1/en not_active Withdrawn
- 1997-02-18 AU AU17916/97A patent/AU1791697A/en not_active Abandoned
- 1997-02-19 CO CO97008748A patent/CO4761060A1/en unknown
- 1997-02-19 AR ARP970100652A patent/AR005903A1/en unknown
- 1997-02-19 PE PE1997000113A patent/PE43198A1/en not_active Application Discontinuation
- 1997-02-19 ID IDP970480A patent/ID15968A/en unknown
- 1997-02-19 ZA ZA9701398A patent/ZA971398B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994002453A1 (en) * | 1992-07-24 | 1994-02-03 | The Wellcome Foundation Limited | Ng-monomethyl-l-arginine hydrochloride derivatives and their use in the treatment of septic shock |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1197486A1 (en) * | 2000-10-13 | 2002-04-17 | Degussa AG | Process for the preparation of 1H-pyrazole-1-carboxamidines |
| US6410745B1 (en) | 2000-10-13 | 2002-06-25 | Degussa Ag | Process for preparing 1-guanylpyrazole acid adducts |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA971398B (en) | 1997-08-20 |
| EP0882014A1 (en) | 1998-12-09 |
| AR005903A1 (en) | 1999-07-21 |
| TW370520B (en) | 1999-09-21 |
| ID15968A (en) | 1997-08-21 |
| CO4761060A1 (en) | 1999-04-27 |
| GB9603522D0 (en) | 1996-04-17 |
| PE43198A1 (en) | 1998-08-26 |
| AU1791697A (en) | 1997-09-10 |
| JP2000504738A (en) | 2000-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4778889A (en) | 2-amino-4-halogeno-6-cyclopropyl-1,3,5-triazines | |
| US5652365A (en) | Process for the production of finasteride | |
| US4152326A (en) | Cyclic sulphonyloxyimides | |
| SE452610B (en) | SETTING DIVERSE RACEMIC CIS-1,2-CYCLOPROPANDICARBOXYLIC ACID DERIVATIVES | |
| US5216161A (en) | Process for preparing 2,5-diamino-4,6-dichloropyrimidine | |
| SU1549484A3 (en) | Method of producing imidazole derivatives | |
| KR20080102422A (en) | Isourea Nitrification Method | |
| US5424432A (en) | Process for the preparation of imidazolutidine | |
| WO1997030972A1 (en) | Process for the preparation of ng-monomethyl-l-arginine hydrochloride | |
| US2701252A (en) | Isoindolenine compounds | |
| JPS6272662A (en) | 4-alkoxy-3-pyrroline-2-one-1-yl-acetic acid alkyl ester and manufacture | |
| US5994557A (en) | Method of acylating amines using N,N'-diacylimidazolone derivatives | |
| US4256897A (en) | Process for the preparation of L-aspartic acid N-thiocarboxyanhydride | |
| US6147215A (en) | Process for producing 1-chlorocarbonyl-4-piperidinopiperidine or hydrochloride thereof | |
| US4275216A (en) | Process for preparing 4(5)-hydroxymethyl 5(4)-lower alkyl imidazoles | |
| CA1130305A (en) | Process for the preparation of n,n'-disubstituted 2-naphthaleneethanimidamide and intermediates used therein | |
| RU2744470C1 (en) | Method for producing isothiobarbamine | |
| SU753360A3 (en) | Method of preparing 6,7-dimethoxy-4-amino-2/4-(2-furoyl)-1-piperazinyl/-quinazoline | |
| US4187225A (en) | Novel synthesis of bis pyrazolone oxonol dyes | |
| WO1990006918A1 (en) | A process for the preparation of 2,4- or 2,4,5-substituted 6-hydroxypyrimidines | |
| US4897495A (en) | Process for the preparation of pyrrolizine derivatives | |
| US4804765A (en) | Process for synthesizing N-[(1'-allyl-2'pyrrolidinyl) methyl]2-methoxy-4,5-azimidobenzamide | |
| US4980495A (en) | Trialkylamine salts of 3-chloro-1,1-dicyano-2-hydroxy-1-propene and preparation of 2-amino-4-chloro-3-cyano-5-formylthiophene | |
| US4985569A (en) | Pyrrolizine derivative and its manufacture | |
| WO2024040111A1 (en) | Process for the preparation and isolation of intermediates of certain mesoionic pesticides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 1997903315 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1997903315 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1997903315 Country of ref document: EP |